TG Therapeutics

TGTX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$33.53

-0.15% today

52W: $25.28 – $46.48

52W Low: $25.28 Position: 38.9% 52W High: $46.48

🔗 Compare Brokers

Key Metrics

P/E Ratio

12.1x

Price-to-Earnings

Forward P/E

13.62x

Forward Price/Earnings

P/S Ratio

8.69x

Price-to-Sales

EV/EBITDA

41.04x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$5.4B

Market Capitalization

Revenue Growth

78%

YoY Revenue Growth

Profit Margin

72.56%

Net profit margin

ROE

102.75%

Return on Equity

Beta

1.75

Market sensitivity

Short Interest

23.01%

% of float sold short

Avg. Volume

2,126,186

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

7 analysts

Avg. Price Target

$44.43

+32.5% upside

Target Range

$15.00 – $60.00

About the Company

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 399 Exchange: NCM